A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
Latest Information Update: 18 Mar 2022
At a glance
- Drugs Belumosudil (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Kadmon Corporation
- 07 Apr 2021 A primary endpoint is added which represents efficacy and intends to asses the difference in proportion (%) of subjects with PASI 75 between belumosudil Cohorts and Placebo Cohort from Baseline at Week 16.
- 07 Jun 2019 Status changed from recruiting to completed.
- 03 Aug 2017 According to a Kadmon media release, approximately 50% patients have been enrolled.